Looking for a partner to develop
anti-AAV antibody detection CDx?
Contact MBL!
MBL’s Commitment to AAV-based gene therapy
MBL has provided diagnostic reagents for rare diseases, such as autoimmune diseases. Contribution to the development of diagnostics in this disease area is one of our primary missions. In recent years, for the treatment of various rare diseases, gene therapy has been widely developed. One of the most common materials used in gene therapy is the Adeno-Associated Viral (AAV) vectors. Test to aid the selection of patients having the preexisting anti-AAV antibodies are commonly used as the Companion Diagnostics (CDx) for the therapeutics using AAV vector. In MBL’s CDx service, we support development and launch of the diagnostic reagents to detect anti-AAV antibodies.
This way, MBL aims to contribute to human health and medical advancement in this disease area as a diagnostic company.
Why MBL as a partner of choice
Since its inception, we have been engaged in in-house R&D, marketing, manufacturing, sales and post-sales follow-ups. Leveraging our wide experience both in RUO and IVD field, we can offer the research use anti-AAV antibody detection kits and the CDx service for AAV-based gene therapy.
Supporting your AAV-based drug development
anti-AAV antibody ELISA kits
Research use only (RUO)
For human, monkey
Detectable serotype: AAV2, 5, 8
CDx Launch in Japan Market
Registration of foreign manufacturer
Regulatory approval
Application for the NHI listing
Feel free to contact MBL!
Anti-AAV antibody detection kits (RUO)
The Anti-AAV Antibody ELISA Kits allow specific and semi-quantitative measurement of anti-AAV antibodies in human or monkey serum using the ELISA method.
‐ Detectable serotype: AAV2, 5, 8
※This kit is the combination of ELISA kits that are stored at two different temperature.
See the product line-up here
(Note; The Anti-AAV Antibody ELISA Kits are limited in the region of sale.)
Our experience with Companion Diagnostics (CDx) for AAV-based therapy
We have launched MEBCDX™ AAV9 test kit in 2020. The MEBCDX™ AAV9 test kit was developed as a CDx to be used as an aid in selecting anti-AAV9 antibody-negative SMA patients for treatment with onasemnogene abeparvovec.
Application and approval of CDx for onasemnogene abeparvovec in Japan
MEBCDX™ AAV9 TEST
